Phamaniseroglin Tablet 30mg

Adult dose

* 5 mg, 10 mg Adults: Administer 5 ∼ 10 mg of nicergoline orally 2 ∼ 3 times daily before meals. Adjust the dose as appropriate according to symptoms. * 30 mg Adults: Administer 30 mg of nicergoline orally once daily before a meal. If the desired effect is not achieved at this dose, the dose may be increased to 60 mg. The dose may be reduced after symptoms improve. For patients with impaired renal function (serum creatinine >175 µmol/L) (2 mg/dL), administer a reduced dose.

This medication should not be used in certain patients. For example, individuals allergic to this drug or ergot alkaloids, patients suffering from acute myocardial infarction or acute hemorrhage, patients taking sympathomimetics, patients with severe bradycardia, patients who have not achieved hemostasis after intracranial hemorrhage, and patients with orthostatic dysregulation should not take this medication. Additionally, patients with mild bradycardia or reduced kidney function should use this medication with caution. Symptoms such as decreased appetite, diarrhea, constipation, nausea, vomiting, epigastric pain, and dry mouth may rarely occur during treatment with this drug. Regarding liver function, there is a possibility of elevated liver enzyme levels, while in the cardiovascular system, dizziness, orthostatic hypotension, hypertension, and hypotension may arise. In the mental and neurological systems, symptoms such as drowsiness, fatigue, headache, tinnitus, weariness, and insomnia may occur rarely. Allergic reactions may present as rash, hives, itching, flushing, and warmth, so caution is advised. This drug may enhance the blood pressure-lowering effect when used with other antihypertensive medications, so blood pressure should be monitored frequently. Moreover, the drug may affect uric acid metabolism, so patients with a history of hyperuricemia or gout should take caution. Care is needed when driving or operating machinery after taking this drug. This medication is metabolized by specific enzymes in the liver (CYP450 2D6), so there may be interactions with other medications related to this enzyme. Pregnant women or those who may become pregnant should carefully consider the benefits and risks of using this drug, while lactating women should either avoid administration or stop breastfeeding. Elderly patients may exhibit decreased bodily functions, so dose adjustments should be made accordingly. Safety in children has not been established, thus use in this group is not recommended. In cases of overdose, a temporary drop in blood pressure may occur, thus careful observation of blood pressure changes and necessary measures should be taken. Lastly, this medication should be stored out of reach of children and kept tightly sealed in its original container to maintain the drug's quality.

Loss of appetite, diarrhea, constipation, nausea, vomiting, sporadic upper abdominal pain or cramping, thirst, elevated ALT, elevated AST, dizziness, orthostatic hypotension, hypertension, increased blood uric acid, blood pressure reduction, drowsiness, fatigue, headache, tinnitus, exhaustion, insomnia, rash, urticaria, itching, flushing, heat sensation, nightmares, mood changes, dyspepsia

This medication should be stored in a tightly closed container protected from light and kept at room temperature between 1 to 30 degrees Celsius. Storing in this manner helps maintain the drug's effectiveness for a longer period.

Appearance

Pale yellow round film-coated tablet

Package unit

100 tablets/bottle, 30 tablets/bottle